Novo Nordisk A/S $NVO Shares Sold by Penserra Capital Management LLC

Penserra Capital Management LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 39.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,748 shares of the company’s stock after selling 3,083 shares during the quarter. Penserra Capital Management LLC’s holdings in Novo Nordisk A/S were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. First Hawaiian Bank grew its stake in Novo Nordisk A/S by 0.6% during the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock worth $1,556,000 after buying an additional 142 shares during the last quarter. Anchor Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock valued at $944,000 after acquiring an additional 150 shares during the period. Xponance Inc. grew its position in shares of Novo Nordisk A/S by 5.0% during the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after acquiring an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC increased its holdings in shares of Novo Nordisk A/S by 3.8% in the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock worth $319,000 after acquiring an additional 166 shares during the period. Finally, Werba Rubin Papier Wealth Management lifted its position in Novo Nordisk A/S by 4.1% in the 2nd quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock valued at $302,000 after purchasing an additional 173 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the subject of several recent analyst reports. Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Morgan Stanley downgraded Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and reduced their price objective for the stock from $59.00 to $47.00 in a research report on Monday, September 29th. TD Cowen decreased their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 19th. HSBC set a $70.00 target price on Novo Nordisk A/S in a research note on Wednesday, October 1st. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $59.20.

Novo Nordisk A/S Trading Up 2.3%

Novo Nordisk A/S stock opened at $50.26 on Thursday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock has a market capitalization of $224.40 billion, a PE ratio of 13.81, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The firm has a 50 day simple moving average of $54.83 and a 200-day simple moving average of $61.22.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.